# RNN 1st Gen Model Allergen plc Pharmaceutical preparations

Stock predictor AI models:
64.37% successful of 87 deals
$ 193.02 Last close price
at 08-may-2020


Model's trade recommendations 3.12% Return for period

-9.44% Annual return

$52.62B Market Cap

β 1.17  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 3.12%
52wk return -28.51%
52wk Range
Sortino ratio -0.66
Sharpe ratio -0.60
Norm. RMSE 0.51%
Downside risk 13.67%
Volatility 0.00%
  • 2.88 (1.91%) Div (Yield)
  • BUY Analysts consensus recommendation

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Allergen plc (AGN) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Sept. 30, 2015.

Market data for AGN model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for AGN.

Model is being retrained on a daily basis.

Float 347M
P/E 9.01
Shares Outstanding 348M
% Held by Insiders 0.36%
% Held by Institutions 78.27%
EPS (last reported FY) $16.35
EPS (last reported Q) $3.74
EPS, estimated (last reported Q) $3.36
Total revenues $16 B
Net income $-4 B